AIHealthcare

Carlsmed, Inc. is a commercial-stage medical technology company developing AI-enabled personalized spine-surgery solutions. Its aprevo® Technology Platform combines AI-assisted surgical-planning software, patient-specific interbody implants designed from imaging data and vertebral anatomy, and single-use surgical instruments for spinal-fusion procedures. The company’s current commercial focus is the United States, where it aims to improve alignment and outcomes while reducing revision procedures and the cost of spine surgery. Carlsmed is a public company listed on Nasdaq under the ticker CARL; it completed its IPO in July 2025, raising approximately $100.5 million. The company reports an estimated U.S. addressable market of approximately $13.4 billion for its lumbar devices and positions itself as a pioneer in personalized spine surgery, although it remains a loss-making growth-stage commercial medtech company rather than an established market leader by scale.